Legato Capital Management LLC Sells 15,726 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Legato Capital Management LLC reduced its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 23.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 51,379 shares of the company's stock after selling 15,726 shares during the quarter. Legato Capital Management LLC owned 0.07% of Kiniksa Pharmaceuticals worth $1,016,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $50,000. CWM LLC boosted its stake in Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth $80,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at $189,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Trading Up 0.5 %

NASDAQ KNSA traded up $0.09 during trading hours on Monday, hitting $19.74. 640,902 shares of the company's stock traded hands, compared to its average volume of 639,943. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The firm has a market capitalization of $1.43 billion, a P/E ratio of -140.99 and a beta of 0.32. The business's fifty day moving average price is $19.79 and its two-hundred day moving average price is $22.80.

Insider Activity

In other news, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now owns 81,975 shares in the company, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,092 shares of company stock valued at $745,589 in the last 90 days. Company insiders own 54.57% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Evercore ISI boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. Finally, Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.